Adamis Pharmaceuticals may face battle for control of its board: Is it shareholder activism or a shakedown?
Print Adamis Pharmaceuticals, a developer of treatments for allergic reactions, opioid overdoses and respiratory ailments, has sidestepped a nasty proxy fight with a disgruntled shareholder — at least for now. But the contentious challenge for control of the unprofitable San Diego company, which Adamis claims is a shakedown, could resurface this fall depending on the outcome of a legal proceeding in Delaware Chancery Court. That is when shareholder Jerald Hammann, a Minnesota-based health-care consultant, will make his case that Adamis’ board of directors breached its fiduciary duty by mo...
Source: sandiegouniontribune.com